Last reviewed · How we verify
Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Adolescents and Adults With Chronic Plaque Psoriasis (MUSE)
This is a phase 1, open label, single arm study in which ARQ-151 cream 0.3% is applied QD for 2 weeks to adolescent subjects with chronic plaque psoriasis involving at least 10% body surface area (BSA) and adult subjects with chronic plaque psoriasis involving at least 20% BSA (excluding scalp). The objectives of this study are to evaluate the exposure and characterize the plasma pharmacokinetic profile and to assess the safety and tolerability of ARQ-151 cream 0.3% administered once daily for 2 weeks to adolescent and adult subjects with chronic plaque psoriasis.
Details
| Lead sponsor | Arcutis Biotherapeutics, Inc. |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 26 |
| Start date | Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu Mar 25 2021 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Plaque Psoriasis
Interventions
- ARQ-151- cream 0.3%
Countries
United States